Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease

NCT03980938 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
15
Enrollment
INDUSTRY
Sponsor class

Stopped Due to the long delay because of COVID-19 and results from another study suggesting a higher dose may be more beneficial, EIP Pharma decided on October 15th, 2020, to end the trial prematurely.

Conditions

Interventions

Sponsor

EIP Pharma Inc

Collaborators